601607 上海医药
2024/03 - 三个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)2.2265.5589.65010.75510.335
总资产报酬率 ROA (%)0.7181.8383.1073.2593.142
投入资产回报率 ROIC (%)1.2203.1465.5105.8705.317

边际利润分析
销售毛利率 (%)11.44412.03613.14213.22513.928
营业利润率 (%)3.4422.9463.8863.8023.744
息税前利润/营业总收入 (%)3.9793.2814.3634.3504.385
净利润/营业总收入 (%)2.6591.9853.0142.9072.921

收益指标分析
经营活动净收益/利润总额(%)93.554103.28880.31175.92088.486
价值变动净收益/利润总额(%)9.0494.7728.53619.71315.232
营业外收支净额/利润总额(%)0.084-8.689-2.342-0.757-0.124

偿债能力分析
流动比率 (X)1.3361.3271.3511.2691.220
速动比率 (X)1.0661.0281.0390.9730.947
资产负债率 (%)62.24562.10560.63263.86063.307
带息债务/全部投入资本 (%)42.73842.10339.01138.29940.469
股东权益/带息债务 (%)127.717130.853149.257145.253132.160
股东权益/负债合计 (%)51.77152.05255.82447.29348.022
利息保障倍数 (X)7.4545.7487.7087.5396.789

营运能力分析
应收账款周转天数 (天)98.90096.60196.88892.45393.875
存货周转天数 (天)51.03955.88254.99749.20253.359